Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033094 · ClinicalTrials.gov registry record
Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 17,566
- Enrollment target
NCT04033094: Completed study, sponsored by Daiichi Sankyo.
NCT04033094 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 17,566 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04033094 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 17,566 participants
- Enrollment target
Study Summary
The main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of MorphaBond ER and selected comparators overall and by age group and census regions using nationally-projected quarterly drug dispensing data and (b) assess the scope and pattern of abuse and clinical outcomes for MorphaBond ER using nationally representative data or data from large geographic areas in different populations. Findings of this study will support the design of formal epidemiology assessment of the risks of addiction, overdose, and death outcomes associated with MorphaBond ER and appropriate comparators in the future.
Interventions
- DRUG Comparator Drug
- DRUG MorphaBond ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,566 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2020-12-31 |
What the finished NCT04033094 record still lists
NCT04033094 is an observational study that tracks outcomes without assigning an intervention. Its 17,566 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Comparator Drug is the first listed.
NCT04033094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04033094 about?
NCT04033094 is a clinical study titled "Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)". The main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of MorphaBond ER and selected comparators overall and by age group and census regions using nationally-projected quarterly drug dispensing data and (b) assess the scope and pattern of abuse and c...
What is the current status of trial NCT04033094?
This trial is currently completed. The enrollment target is 17,566 participants. The study started on 2017-10-16. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04033094?
The interventions under investigation include: Comparator Drug (DRUG), MorphaBond ER (DRUG).
Who is sponsoring clinical trial NCT04033094?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07290361 · 17,587 participants · NA
Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)
- NCT06272110 · 17,500 participants
Promoting Equitable Access to Language Services in Health and Human Services
- NCT07108660 · 17,800 participants · NA
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
- NCT06245187 · 17,198 participants
Get With the Guidelines Atrial Fibrillation Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI